3 unchanged sentences
(c) Insider Trading Arrangements and Policies.
−Removed: On August 8, 2024 , Jospeh Shulman , the Company’s Chief Technical Officer , adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 73,203 shares of the Company’s common stock until November 5, 2025 .
−Removed: On August 8, 2024 , Jennifer Kayden Lee , the Company’s EVP, Head of North America , adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 71,050 shares of the Company’s common stock until September 1, 2025 .
−Removed: Other than as disclosed above, during the three months ended September 30, 2024, no director or officer of the Company adopted or terminated a “ Rule 10b5-1 trading arrangement ” or “ non-Rule 10b5-1 trading arrangement ,” as each term is defined in Item 408(a) of Regulation S-K.
+Added: On February 28, 2025 , David McGirr , a member of the Company’s board of directors , adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 65,431 shares of the Company’s common stock until November 7, 2025 .
+Added: On February 28, 2025 , Hunter Smith , the Company’s Chief Financial Officer , adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 121,185 shares of the Company’s common stock until May 30, 2026 .
+Added: On March 3, 2025 , David Meeker , the Company’s Chairman, President, and Chief Executive Officer , adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 43,621 shares of the Company’s common stock until November 7, 2025 .
+Added: On March 11, 2025 , Christopher German , the Company’s Corporate Controller and Chief Accounting Officer , adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 7,386 shares of the Company’s common stock until June 10, 2026 .
+Added: Other than as disclosed above, during the three months ended March 31, 2025, no director or officer of the Company adopted or terminated a “ Rule 10b5-1 trading arrangement ” or “ non-Rule 10b5-1 trading arrangement ,” as each term is defined in Item 408(a) of Regulation S-K.
Incorporated by Reference
19 unchanged sentences
RHYTHM PHARMACEUTICALS, INC.
−Removed: November 6, 2024
President and Chief Executive Officer
(Principal Executive Officer)
−Removed: November 6, 2024
/s/ Hunter C.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.